La tomographie par émission de positons (TEP) est une technique d’imagerie moléculaire avec de meilleures performances que la tomographie par émission monophotonique. Son utilisation contribue à l’amélioration des prises en charge des patients. Dans les centres dépourvus de cyclotrons, le 68Ga disponible à partir d’un générateur constitue une alternative pour le développement de traceurs TEP. Pour pouvoir développer des 68Ga-traceurs, un travail de caractérisation de la qualité des éluats a été effectué. Des méthodes de marquage adaptées ont été mises en place et validées. Nous nous sommes intéressés à trois cibles moléculaires particulièrement intéressantes dans les pathologies cardiovasculaires: les récepteurs de la somatostatine (SSTR) surexprimés dans les tumeurs neuroendocrines (TNE) mais constituant aussi une cible d’intérêt dans les pathologies cardiovasculaires à composante inflammatoire ; la phosphatidylsérine (PS), un marqueur de l’apoptose cellulaire et de l’activation plaquettaire ; la P-sélectine, un marqueur des activations plaquettaire et endothéliale. Les traceurs suivants ont été développés: 1) Analogues de la somatostatine ciblant les SSTR: a)68Ga-DOTANOC validé pour l’imagerie des TNE-Gastroentéropancréatiques dans le cadre d’un essai clinique multicentrique. b) 68Ga-NODAGANOC testé in vitro sur des cellules d’adénocarcinome pancréatique. Cette validation initiale dans l’application la plus fréquente(oncologie) a pour objectif de faciliter le passage vers des applications cardiovasculaires futures (athérosclérose, myocardite...) ; 2) Un peptide ciblant la PS : le 68Ga-P04087 ; 3) Un polysaccharide ciblant la P-sélectine: 68Ga-NODAGA-Asphy. Les deux derniers traceurs ont été testés sur un modèle d’endocardite infectieuse chez le rat. / The Positron emission tomography (PET) is a molecular imaging technique with usually better performances than Single-Photon Emission Computed Tomography. Consequently, the use of PET and appropriate tracers could enable clinicians to make a better therapeutic decision, thus improving the management of patients. In centers without cyclotrons, 68Ga available from a generator is an alternative for the development of PET tracers. In order to develop 68Ga labeled-molecules, a characterization of the quality of the eluates was performed. Radiolabeling techniques adapted to the quality of the starting material were developed and validated. In this thesis we focused on three particularly interesting molecular targets in cardiovascular pathologies: somatostatin receptors (SSTR), overexpressed in neuroendocrine tumors (NETs) but also constituting a target of interest in cardiovascular diseases with an inflammatory component; phosphatidylserine (PS), a marker of cell apoptosis and platelet activation; P-selectin, a marker of platelet and endothelial activation.The following tracers have been developed: 1) Somatostatin analogues which target SSTR: a) 68Ga-DOTANOC validated for Gastroenteropancreatic-NETs imaging and used in a multicenter clinical trial. b) 68Ga-NODAGANOC tested in vitro on pancreatic adenocarcinoma cells. This initial validation in the most common application (oncology) aims to facilitate the transition to future cardiovascular applications (atherosclerosis, myocarditis ...) 2) A peptide for PS targeting: 68Ga-P04087; 3) A polysaccharide for P-selectin targeting: 68Ga-NODAGA-Asphy. The last two radiolabeled molecules were tested in a rat model of infective endocarditis.

Dans cet ouvrage sera décrite la synthèse de nouveaux analogues du sialyl Lewis X (sLex). A cet effet, nous avons préparé une librairie d’analogues synthétisée à partir d’une approche mettant en jeu un «espaceur» acyclique permettant d’avoir un biais conformationnel que nous avons défini comme la stratégie ATC-B. Nous avions déjà démontré que certains analogues portant un groupe benzoate en C-2 et en C-4 du galactose présentent une activité 50 fois supérieure à celle du sLex. Nous avions par ailleurs démontré qu’en l’absence du benzoate en C-2, l’activité devient alors trois fois plus faible. A présent, il paraissait interessant de synthétiser des analogues ayant seulement un groupe benzoate en C-4 pour evaluer l’impact de ce groupement sur la puissance de nos analogues. Par le passé, nous avions également mis en évidence le rôle des esters sur l’activité des analogues portant un «espaceur» acyclique dans le cadre de la stratégie ATC-B. Nous effectuerons donc des variations à ce niveau pour en évaluer l’impact. Enfin, nous avons préparé une nouvelle famille d’analogues de type dimère. Ceux-ci seront constitués de 2 unités des composés monomériques synthétisés précédemment. La synthèse de ces dimères fera l’emploi de la «Click Chemistry». Cette étude nous mènera a vous présenter la synthèse de ces composés et la méthodologie employée. / This work describes the synthesis of novel sialyl Lewis X (sLex) analogues. To this end, we have prepared a library of analogues by implementing a strategy that makes use of an Acyclic Tether which allows for defined Conformational Bias (ATCB strategy). We have previously shown that analogues bearing a benzoate group at both positions C-2 and C-4 of the galactose exert an activity 50-fold greater than that of sLex. Indeed, removing the benzoate at position C-4 while keeping the one at C-2 led to a three fold decrease in potency. We are currently preparing the corresponding analogues that have the benzoate only at position C-4 in order to fully evaluate its impact on the potency of the analogue. We have also previously elucidated the role of esters on the activity of analogues that have acyclic tether as part of the ATC-B strategy. Variations have been made at the level of the ester and their impact has been evaluated. Lastly, we have prepared a novel family of analogues consisting of two identical monomeric subunits linked together. Synthesis of these dimers was performed via «Click Chemistry». This study describes the synthesis of the compounds and the methodology employed.

A disfunção microvascular, envolvendo células endoteliais, plaquetas e leucócitos, está presente na hipertensão arterial pulmonar (HAP), associando-se a risco aumentado de trombose e menor sobrevida. Estudos sobre disfunção microvascular são escassos em outras formas da doença que não a idiopática. Os objetivos do estudo foram: caracterizar a disfunção microvascular em diferentes formas de HAP através da dosagem de marcadores bioquímicos, avaliando possíveis correlações com índices de gravidade; investigar os efeitos da administração de rosuvastatina em níveis circulantes de marcadores de disfunção microvascular nesses pacientes; e investigar possível associação entre o nível plasmático dos marcadores e prognóstico. Foram incluídos sessenta pacientes: 14 com HAP idiopática ou hereditária, e 46 com HAP associada a cardiopatia congênita (HAPCCg) sem hipoxemia (N=18) ou com hipoxemia (N=28), com idades entre 13 e 60 anos. Foram dosados os níveis plasmáticos circulantes do antígeno do fator de von Willebrand (vWF:Ag), ativador tecidual do plasminogênio (t-PA); inibidor do ativador do plasminogênio (PAI-1), fator de necrose tumoral (TNF-), proteína C reativa (PCR), selectina-P; interleucina-6 (IL-6); e interleucina-10 (IL -10), na condição basal e após 30, 60 e 180 dias de tratamento, por método imunoenzimático. Após randomização, administrouse placebo (N=30) ou dose única oral diária (10mg) de rosuvastatina (N=30), por seis meses. Dados demográficos e funcionais como idade, distância caminhada em seis minutos, saturação periférica de oxigênio em repouso e após esforço, bem como hematócrito, também foram registrados. Pacientes com HAPCCg foram acompanhados por um período de 0,7 a 4,0 anos (mediana de 3,6 anos). Na condição basal, excetuando-se TNF- e PCR, todas as proteínas apresentaram-se significantemente elevadas em relação aos controles (p<0,001), havendo correlação com índices de gravidade clínica. No estudo com rosuvastatina, houve redução significante nos níveis de selectina-P em relação ao placebo (p=0,037), ao longo do tratamento. Houve melhora na saturação periférica de oxigênio após seis minutos de caminhada, no grupo estatina, em pacientes com HAPCCg com hipoxemia, em relação ao placebo. Considerando-se o período de acompanhamento, em portadores de HAPCCg, níveis plasmáticos persistentemente elevados do vWF:Ag (média de quatro determinações), acima do nível correspondente ao percentil 95 dos controles (139 U/d/L) associaram-se maior risco de morte (razão de risco 6,56, IC 95% 1,46 a 29,4, p=0.014), sem alteração após ajustamento para variáveis demográficas, funcionais e de tratamento, à análise multivariada. Assim, a disfunção microvascular está presente em indivíduos com HAP idiopática, hereditária ou associada a cardiopatias congênitas. Na HAP, o uso crônico de rosuvastatina em dose baixa associase à redução do nível circulante de selectina-P, e propicia aumento na saturação periférica de oxigênio ao final do exercício, em indivíduos com HAPCCg e hipoxemia. Em indivíduos portadores de HAPCCg, níveis plasmáticos persistentemente elevados do vWF:Ag são indicativo de pior prognóstico / Microvascular dysfunction, involving endothelial cells, platelets and leukocytes, is present in pulmonary arterial hypertension (PAH), and is associated to higher risk to thrombotic complications and mortality. Most data about microvascular dysfunction in PAH do not include other forms of the disease beyond idiopathic PAH. The present study was planned to measure plasma levels microvascular dysfunction markers in two different forms of PAH, and investigate possible correlations with indices of severity of the disease; to investigate the effects of chronic rosuvastatin administration versus placebo on the circulating levels of these markers; and to investigate possible associations between levels of these parameters and prognosis. Sixty patients (aged 13 to 60 years) were included, 14 with idiopathic or hereditary PAH, and 46 with congenital heart disease-associated PAH (CHDPAH), in the absence (N=18) or presence (N=28) of hypoxemia. Plasma levels of von Willebrand factor antigen (vWF:Ag), tissue-plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor alpha (TNF-), reactive C protein (RCP), P-selectin, interleukin-6 (IL- 6), and interleukin-10 (IL-10) were measured before treatment and 30, 90, and 180 days on treatment using high-sensitivity enzyme-linked immunosorbent assay kits. Patients were randomly assigned to placebo (N=30) or a single oral dose of rosuvastatin (N=30), 10mg/day, for six months. Demographic and functional data such as age, six-minute walk distance, peripheral oxygen saturation at rest and at the end of the six-minute walk, as well as the hematocrit, were recorded. Patients with CHDPAH were followed-up for 0.7 to 4.0 years (median 3.6 years). At baseline, levels of all proteins (except TNF- and RCP) were significantly increased in patients versus controls (p<0,001), and correlated significantly with indices of severity of the disease. P-selectin level was lower in the rosuvastatin group compared with placebo throughout the treatment (p = 0.037). In hypoxemic CHDPAH patients, the peripheral oxygen saturation, at the end of the six-minute walk, was higher in the rosuvastatin group, compared with placebo. During the follow-up of patients with CHDPAH, an average vWF:Ag (mean of four determinations) above the level corresponding to the 95th percentile of controls (139 U/dL) was associated with a high risk of death (hazard ratio 6.56, 95% CI 1.46 to 29.4, p=0.014). This was not modified after adjustment for demographic, functional and treatment-related variables in multivariate analysis. In conclusion, microvascular dysfunction is present in individuals with idiopathic, hereditary and the congenital heart disease-associated PAH. The chronic use of low-dose rosuvastatin is associated to reduction of circulating levels of P-selectin. In patients with CHDPAH with hypoxemia, rosuvastatin also increases peripheral oxygen saturation during exercise. In CHDPAH patients, a sustained increase in plasma vWF:Ag is indicative of poor prognosis

Résumé Responsable de près de 7 millions de décès prématurés par an à travers le monde, la pollution atmosphérique représente un problème sanitaire mondial majeur. L’exposition humaine à la pollution particulaire dont les émissions de diesel représentent la principale source, est responsable d’une élévation de la mortalité et de l’incidence d’événements cardiovasculaires. Les mécanismes physiopathologiques sous-tendant cette toxicité aigue restent à ce jour largement méconnus. A l’aide d’une méthodologie d’exposition standardisée aux émissions de diesel, nous avons exploré les effets vasculaires périphériques et pulmonaires ainsi que les effets hémostatiques et plaquettaires secondaires à l’inhalation particulaire chez des sujets sains. L’étude dynamique de la microcirculation périphérique par Laser Doppler Imager nous a permis de démontrer une altération de la vasomotricité endothélium-dépendante induite par l’exposition aux émissions de diesel. La dysfonction observée est associée à une diminution de la biodisponibilité locale du NO ainsi qu’à une production radicalaire accrue au sein de la cellule endothéliale. Au cours d’une épreuve dynamique d’élévation du débit cardiaque par infusion de dobutamine, l’exposition aiguë aux émissions de diesel entraîne une élévation de la résistance vasculaire pulmonaire et une diminution de la distensibilité vasculaire pulmonaire mesurées par échocardiographie. Enfin, l’expression de surface des marqueurs d’activation plaquettaire CD62p (P-selectine) et CD63 est augmentée après exposition aux émissions de diesel, en corrélation avec la quantité de particules inhalées et constitue ainsi un état d’activation plaquettaire accru sans toutefois de modification de l’agrégation plaquettaire. A travers ces effets vasculaires systémiques et pulmonaires ainsi que ces effets hémostatiques, l’exposition aux émissions de diesel entraîne une toxicité cardiovasculaire aiguë, agissant en synergie, capable de déclencher la survenue d’événements cardiovasculaires.Abstract Responsible for up to 7 million deaths/year, air pollution is a major worldwide health burden. Particulate human exposure mainly originates from diesel exhaust and is associated with an increased cardiovascular mortality and an increased onset of cardiovascular events. Physiopathologic mechanisms underlying this acute toxicity remain largely unknown. We used a standardized diesel exhaust exposure protocol to explore not only the peripheral and pulmonary vascular effects, but also the hemostatic and platelet modifications in healthy subjects after particulate inhalation. Diesel exhaust exposure impairs the endothelium-dependant vasodilation during a dynamic evaluation of the peripheral microcirculation assessed by Laser Doppler Imager, whilst the endothelial independent vasodilatation remains unaffected. Vascular dysfunction is associated to a decreased local NO bioavailability and an increased endothelial reactive oxygen species production. During a dynamic cardiac stress test using continuous dobutamine infusion, acute diesel exhaust exposure induces an increased pulmonary vascular resistance associated to a decreased pulmonary vascular distensibility, both evaluated by echocardiography. Finally, platelet activation is modified after diesel exhaust exposure with an increased CD62p (P-selectin) and CD63 platelet surface expression, correlated with the total amount of inhaled particles. We observed a state of platelet activation without change in platelet aggregation. Through these multiples effects, combining systemic and pulmonary vascular impairment with platelet prothrombotic modifications, diesel exhaust exposure induces an acute cardiovascular toxicity, which can synergistically trigger acute events. / Doctorat en Sciences médicales (Médecine) / info:eu-repo/semantics/nonPublished

1 Cardiovascular risks in chronic airway disease in childhood The aim of this thesis was to evaluate cardiovascular risk by using a combined diagnostic approach by measuring RHI and specific biochemical markers in patients with chronic respiratory disease, where we could assume a possible risk of CVD. A total of 119 probands were examined, including 22 patients with cystic fibrosis (CF) and 52 asthma patients. We evaluated RHI using a new plethysmographic method that has a number of advantages over the ultrasonographic methods used in other studies, including non-invasiveness, high sensitivity, low biological variability and objectivity due to automatic processing. Of the biochemical parameters, we measured 4 biomarkers in relation to endothelial dysfunction (ED): hsCRP, ADMA, E-selectin, and VCAM-1. We compared RHI and biomarkers in CF and asthma patients with healthy controls and sought mutual correlations. We did not prove a statistically significant difference in RHI between the test groups with CF children but we confirmed the decreasing trend of RHI since adolescence and significantly lower RHI values in CF adults, confirming the progressive development of atherogenesis and worsening of ED with age. Biochemical parameters showed significantly higher levels of hsCRP, sVCAM-1 and E-selectin in CF...

No description available.

INTRODUÇÃO: Eventos vasculares e imunológicos são centrais na patogênese da granulomatose com poliangeíte (GPA). Moléculas de adesão celular tem papel fundamental no recrutamento de células inflamatórias do sangue para os tecidos. Diferentes leitos vasculares apresentam particularidades na expressão de moléculas de adesão celular explicando talvez parte da especificidade da GPA por determinados órgãos. A elevação no nível sérico de moléculas de adesão celular e aumento da expressão destas em amostras de biópsia renal já foram demonstrados em pacientes com vasculite ANCA associada. No entanto, o fenômeno ainda não foi estudado in situ no pulmão. OBJETIVO: O objetivo deste estudo foi analisar o padrão de expressão endotelial pulmonar de três moléculas de adesão celular na GPA, in situ: molécula de adesão intercelular 1 (ICAM-1), molécula e adesão vascular 1 (VCAM-1) e E-selectina. MÉTODOS: Examinou-se a expressão endotelial de ICAM-1, VCAM-1, E-selectina usando marcação imuno-histoquímica em secções de pulmão fixadas e parafinadas de lesões de GPA (n = 8 casos, 90 secções transversais de vasos analisados). Foram também analisados controles positivos: amostras de pulmão de doença intersticial associada à esclerodermia (SScl) (n = 8 casos, 96 secções transversais de vasos analisados) e controles negativos (n = 9 casos, 90 secções transversais de vasos analisados). A quantificação imuno-histoquímica foi realizada no aumento de 400x usando a técnica de point-counting. RESULTADOS: ICAM-1: A expressão endotelial mediana de ICAM-1 esteve aumentada de forma semelhante na GPA e na SScl (81% and 73%, respectivamente; p = 0.97). A comparação com o grupo controle (26.3%) revelou diferença estatisticamente significativa entre controle e GPA (p <0.001) quanto entre controle e SScl (p = 0.017). VCAM-1: A expressão mediana de VCAM-1 esteve significativamente aumentada na GPA se comparada a SScl (79.5% vs 41.4%; p = 0.012), no entanto, a expressão endotelial de VCAM-1 nos controles também esteve moderadamente aumentada (49.8%) e não houve diferença estatística entre SScl e controles ( p = 0.549) ou entre GPA e controles (p = 0.242). E-selectina: A expressão endotelial mediana de E-selectina esteve aumentada de forma semelhante na GPA e SScl (100% e 88.2%, respectivamente; p = 0.272). A comparação com o grupo controle (13.8%) revelou diferença estatisticamente significativa entre controle e GPA (p < 0.001) e controle e SScl (p = 0.045). CONCLUSÃO: Esses achados evidenciam o fenômeno de ativação endotelial pulmonar in situ em lesões de GPA. O perfil de expressão de moléculas de adesão parece ter particularidades em diferentes doenças a exemplo da maior expressão de VCAM-1 na GPA em relação à SScl. Essas observações contribuem para o conhecimento fisiopatogênico na GPA. / INTRODUCTION: Vascular and immunologic processes are central to the pathogenesis of granulomatosis with polyangiitis (GPA). Endothelial cellular adhesion molecules have a central role in recruiting leukocytes to sites of inflammation. Moreover, different vascular beds are phenotypically and functionally distinct with regard to expression of cellular adhesion molecules. They have been shown to be elevated in sera and in renal biopsies of patients with active ANCA-associated vasculitis. Despite of that, the expression of cellular adhesion molecules has not been studied in situ in the lungs. OBJECTIVE: Within this context, the aim of this study was to analyze the in situ pulmonary endothelial immunohistochemical pattern of expression of three cellular adhesion molecules in GPA: intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and E-selectin . METHODS: For such, we examined formalin-fixed, paraffin-embedded sections of lung lesions of GPA (n = 8 cases, 90 transverse sections of pulmonary vessels), negative controls which were obtained from autopsies ( n = 9 cases, 90 transverse sections of pulmonary vessels analyzed) and positive controls which were cases of interstitial lung disease associated with systemic sclerosis (SScl) (n = 8 cases, 96 transverse sections of pulmonary vessels). The quantification of the immunohistochemical staining was performed at x400 magnification using the technique of point-counting, previously described. RESULTS: ICAM-1: Median endothelial expression of ICAM-1 was similarly enhanced in GPA and SScl (81% and 73%, respectively; p = 0.97). When compared to controls (26.3%), both GPA (p <0.001) and SScl (p = 0.017) had significantly higher endothelial expression of ICAM-1. VCAM-1: Median endothelial expression of VCAM-1 was significantly enhanced in GPA when compared to SScl (79.5% vs 41.4%; p = 0.012), however the endothelial expression of VCAM-1 in the controls was also moderately enhanced (49.8%) and no statistically significant difference was found between SScl and controls ( p = 0.549) or between GPA and controls (p = 0.242). E-selectin: Median endothelial expression of E-selectin was similarly enhanced in GPA and SScl (100% and 88.2%), respectively; p = 0.272. When compared to controls (13.8%), both GPA (p < 0.001) and SScl (p = 0.045) had significantly higher endothelial expression of E-selectin. CONCLUSION: These observations are evidence of in situ pulmonary endothelial activation in lesions of GPA. The profile of expression of cellular adhesion molecules seems to be particular for each disease state and timing as evidenced by the enhanced expression of VCAM-1 in GPA when compared to SScl. These observations add information to the pathogenetic knowledge of GPA

INTRODUÇÃO: Eventos vasculares e imunológicos são centrais na patogênese da granulomatose com poliangeíte (GPA). Moléculas de adesão celular tem papel fundamental no recrutamento de células inflamatórias do sangue para os tecidos. Diferentes leitos vasculares apresentam particularidades na expressão de moléculas de adesão celular explicando talvez parte da especificidade da GPA por determinados órgãos. A elevação no nível sérico de moléculas de adesão celular e aumento da expressão destas em amostras de biópsia renal já foram demonstrados em pacientes com vasculite ANCA associada. No entanto, o fenômeno ainda não foi estudado in situ no pulmão. OBJETIVO: O objetivo deste estudo foi analisar o padrão de expressão endotelial pulmonar de três moléculas de adesão celular na GPA, in situ: molécula de adesão intercelular 1 (ICAM-1), molécula e adesão vascular 1 (VCAM-1) e E-selectina. MÉTODOS: Examinou-se a expressão endotelial de ICAM-1, VCAM-1, E-selectina usando marcação imuno-histoquímica em secções de pulmão fixadas e parafinadas de lesões de GPA (n = 8 casos, 90 secções transversais de vasos analisados). Foram também analisados controles positivos: amostras de pulmão de doença intersticial associada à esclerodermia (SScl) (n = 8 casos, 96 secções transversais de vasos analisados) e controles negativos (n = 9 casos, 90 secções transversais de vasos analisados). A quantificação imuno-histoquímica foi realizada no aumento de 400x usando a técnica de point-counting. RESULTADOS: ICAM-1: A expressão endotelial mediana de ICAM-1 esteve aumentada de forma semelhante na GPA e na SScl (81% and 73%, respectivamente; p = 0.97). A comparação com o grupo controle (26.3%) revelou diferença estatisticamente significativa entre controle e GPA (p <0.001) quanto entre controle e SScl (p = 0.017). VCAM-1: A expressão mediana de VCAM-1 esteve significativamente aumentada na GPA se comparada a SScl (79.5% vs 41.4%; p = 0.012), no entanto, a expressão endotelial de VCAM-1 nos controles também esteve moderadamente aumentada (49.8%) e não houve diferença estatística entre SScl e controles ( p = 0.549) ou entre GPA e controles (p = 0.242). E-selectina: A expressão endotelial mediana de E-selectina esteve aumentada de forma semelhante na GPA e SScl (100% e 88.2%, respectivamente; p = 0.272). A comparação com o grupo controle (13.8%) revelou diferença estatisticamente significativa entre controle e GPA (p < 0.001) e controle e SScl (p = 0.045). CONCLUSÃO: Esses achados evidenciam o fenômeno de ativação endotelial pulmonar in situ em lesões de GPA. O perfil de expressão de moléculas de adesão parece ter particularidades em diferentes doenças a exemplo da maior expressão de VCAM-1 na GPA em relação à SScl. Essas observações contribuem para o conhecimento fisiopatogênico na GPA. / INTRODUCTION: Vascular and immunologic processes are central to the pathogenesis of granulomatosis with polyangiitis (GPA). Endothelial cellular adhesion molecules have a central role in recruiting leukocytes to sites of inflammation. Moreover, different vascular beds are phenotypically and functionally distinct with regard to expression of cellular adhesion molecules. They have been shown to be elevated in sera and in renal biopsies of patients with active ANCA-associated vasculitis. Despite of that, the expression of cellular adhesion molecules has not been studied in situ in the lungs. OBJECTIVE: Within this context, the aim of this study was to analyze the in situ pulmonary endothelial immunohistochemical pattern of expression of three cellular adhesion molecules in GPA: intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and E-selectin . METHODS: For such, we examined formalin-fixed, paraffin-embedded sections of lung lesions of GPA (n = 8 cases, 90 transverse sections of pulmonary vessels), negative controls which were obtained from autopsies ( n = 9 cases, 90 transverse sections of pulmonary vessels analyzed) and positive controls which were cases of interstitial lung disease associated with systemic sclerosis (SScl) (n = 8 cases, 96 transverse sections of pulmonary vessels). The quantification of the immunohistochemical staining was performed at x400 magnification using the technique of point-counting, previously described. RESULTS: ICAM-1: Median endothelial expression of ICAM-1 was similarly enhanced in GPA and SScl (81% and 73%, respectively; p = 0.97). When compared to controls (26.3%), both GPA (p <0.001) and SScl (p = 0.017) had significantly higher endothelial expression of ICAM-1. VCAM-1: Median endothelial expression of VCAM-1 was significantly enhanced in GPA when compared to SScl (79.5% vs 41.4%; p = 0.012), however the endothelial expression of VCAM-1 in the controls was also moderately enhanced (49.8%) and no statistically significant difference was found between SScl and controls ( p = 0.549) or between GPA and controls (p = 0.242). E-selectin: Median endothelial expression of E-selectin was similarly enhanced in GPA and SScl (100% and 88.2%), respectively; p = 0.272. When compared to controls (13.8%), both GPA (p < 0.001) and SScl (p = 0.045) had significantly higher endothelial expression of E-selectin. CONCLUSION: These observations are evidence of in situ pulmonary endothelial activation in lesions of GPA. The profile of expression of cellular adhesion molecules seems to be particular for each disease state and timing as evidenced by the enhanced expression of VCAM-1 in GPA when compared to SScl. These observations add information to the pathogenetic knowledge of GPA

Inflammatory bowel diseases, (IBD), are a group of chronic disorders of the gastro-intestinal tract, and include Crohn’s disease (CD) and Ulcerative Colitis (UC). The pathogenesis is not known, but involves at least in part a loss of tolerance towards the commensal colonic microbiota. In this thesis, we show in animal models of CD and UC that the colonic mucosal blood flow increased compared to healthy animals. This blood flow increase is due to an up regulation of endothelial nitric oxide synthase (NOS). Further, we show in the UC model that the thickness of the firmly adherent colonic mucus layer increased compared to healthy animals. This increase is due to an up regulation of inducible NOS in the epithelium. Both the blood flow and mucus thickness increase appear to be protective mechanisms.  We demonstrate that the firmly adherent colonic mucus layer acts as a partial barrier towards luminal bacteria. In the UC model, this barrier is destroyed, causing increased bacterial translocation. The adhesion molecule P-selectin was up regulated in the UC model, leading to increased interactions between leukocytes and the endothelium, but also increased interactions between platelets and the endothelium. This indicates that not only leukocytes, but also platelets are involved in colonic inflammation. The addition of the probiotic bacterial strain Lactobacillus reuteri prevented disease by normalizing P-selectin levels and endothelial interactions with leukocytes and platelets. Lactobacillus reuteri also decreased bacterial translocation over the epithelium. In summary, this thesis highlights the importance of colonic barrier functions, and investigates the role of the microbiota in experimental IBD.

Erkrankungen des Herz-Kreislaufsystems sind die häufigste Todesursache in Deutschland. Eine gestörte Funktion des Gefäßendothels spielt bei der Entstehung von Herz-Kreislauferkrankungen eine Schlüsselrolle. Das Risiko einer kardiovaskulären Erkrankung ist bei Diabetikern stark erhöht. Der Transkriptionsfaktor COUP-TFII spielt eine essentielle Rolle im Glukosemetabolismus. Gleichzeitig ist er für die Differenzierung von Endothelzellen von großer Bedeutung. Für die Differenzierung und Aufrechterhaltung des arteriellen und venösen Phänotyps von Endothelzellen sind dabei maßgeblich der NOTCH-Signalweg und insbesondere die Transkriptionsfaktoren HEY2 (arteriell) und COUP-TFII (venös) verantwortlich. Gesteigerte Glukosespiegel könnten somit Auswirkungen auf die Differenzierung von Endothelzellen haben und damit einen neuen Mechanismus für das erhöhte Risiko von Gefäßerkrankungen bei Diabetikern darstellen. Im Rahmen der Arbeit konnte die exklusive Expression von COUP-TFII im Zellkern von humanen venösen Endothelzellen nachgewiesen werden. Humane arterielle Endothelzellen zeigten keine Expression von COUP-TFII. Außerdem konnte im Rahmen der Arbeit erstmals die spezifische Expression von COUP-TFII in humanen Endothelzellen der Koronararterie nachgewiesen werden. Die Untersuchung der COUP-TFII Promotoraktivität konnte das Expressionsmuster von COUP-TFII bestätigen. Der Promotor zeigte sowohl in den venösen Endothelzellen der humanen Nabelschnur als auch in den humanen Endothelzellen der Koronararterie Aktivität. Die kurzzeitige Stimulation von venösen Endothelzellen mit Glukose führte zu einem starken Anstieg der COUP-TFII Expression. Eine Translokation von COUP-TFII aus dem Zellkern in das Zytoplasma konnte nicht nachgewiesen werden. Die Langzeitstimulation führte interessanterweise zu einer Verminderung der COUP-TFII Expression und zu einer Erhöhung der Expression von E-Selektin. In beiden Fällen zeigte sich keine Beeinträchtigung der Expression durch Insulin. Die durchgeführten Untersuchungen schließen eine Beteiligung des AKT-Signalweges an der Regulation aus. Es zeigte sich jedoch, dass humane venöse Endothelzellen als Insulin-sensitives Gewebe mit funktionsfähigem AKT-Signalweg einzustufen sind. Stimulationsversuche mit L-Glukose zeigten keine Regulation der COUP-TFII Expression. Eine osmotische Wirksamkeit der hohen Glukosekonzentration auf die Expression von COUP-TFII konnte somit ausgeschlossen werden. Die Deletionsanalyse des COUP-TFII Promotors konnte einen Glukose-sensitiven Bereich innerhalb des COUP-TFII Promotors identifizieren. Weiterhin konnte die Repression der Aktivität des COUP-TFII Promotors durch Hypoxie nachgewiesen werden. Eine der wichtigen Aufgaben von Endothelzellen ist die von der endothelialen NO-Synthase (eNOS) katalysierte Bildung von Stickstoffmonoxid (NO). NO hemmt die Expression des Adhäsionsmoleküls E-Selektin. Eine verringerte NO-Produktion hat die Ausbildung einer endothelialen Dysfunktion zur Folge. In dieser Arbeit konnte erstmals eine Erhöhung der eNOS Expression nach Verminderung der Expression von COUP-TFII in humanen venösen Endothelzellen gezeigt werden. Diese könnte die Ursache für die Verminderung der E-Selektin Expression nach Herabregulation von COUP-TFII sein. Durch die Anwendung einer Plattenkegel-Viskometer-Apparatur konnte gezeigt werden, dass die NO-Abgabe entscheidend von den Strömungsbedingungen und Scherkräften abhängig ist. Die Stimulation arterieller Endothelzellen mit laminarer oder oszillatorischer Schubspannung führte zu einer Erhöhung der NO-Abgabe. Turbulente Schubspannung zeigte dagegen keinen Einfluss auf die NO-Abgabe. Durch Überexpression von COUP-TFII in Kombination mit laminarer Schubspannung wurde die NO-Abgabe weiter gesteigert. Die gezeigte direkte Regulation der HEY2 und COUP-TFII Promotoraktivität durch geänderte Strömungsbedingungen spielt in diesem Prozess möglicherweise eine bedeutende Rolle. Die beschriebene Regulation von COUP-TFII durch Glukose in Endothelzellen könnte eine neue Erklärung für die gesteigerte Rate an Gefäßerkrankungen von Typ2-Diabetikern darstellen. Bei der Regulation der endothelialen NO-Synthase und E-Selektin durch COUP-TFII handelt es sich möglicherweise um einen neuen, anti-adhäsiven Feedback-Mechanismus, der zur Verringerung der Leukozyten-Adhäsion an Endothelzellen und damit zur Gefäßprotektion beitragen könnte. Die differentielle Expression der arteriellen Markergene HEY2 und CD44 konnte in humanen venösen und arteriellen Endothelzellen gezeigt werden. Die Untersuchung der Expression von FOXC1 legt nahe, dass es sich bei diesem Transkriptionsfaktor ebenfalls um ein in Endothelzellen arteriovenös differentiell exprimiertes Gen handelt. Die differentielle Exprimierung von HEY2 in Endothelzellen konnte auf transkriptioneller Ebene zusätzlich durch ein HEY2 Promotor Funktionsassay gezeigt werden. Die Überexpression der NOTCH1 intrazellulären Domäne führte zur Induktion der endogenen Expression der NOTCH-Zielgene HEY1 und HEY2 in HEK 293T Zellen. In dem Zelltyp durchgeführte Reportergenassays zeigten ebenfalls eine deutliche Aktivierung des HEY2 Promotors durch die Überexpression der NOTCH1 intrazellulären Domäne. Durch eine Deletionsanalyse konnte der Bereich, der für die Aktivierung verantwortlichen DNA-Sequenz-Motive stark eingegrenzt werden. Weiterhin konnte die Induktion des HEY2 Promotors durch VEGF und seine Repression durch einen γ-Sekretase Inhibitor nachgewiesen werden. Die Überexpression der NOTCH1 intrazellulären Domäne führte zur Verringerung der mRNA- und Protein-Expression von COUP-TFII in HEK 293T Zellen. Dieses Ergebnis konnte zusätzlich durch ein COUP-TFII Promotor Aktivitätsassay nach Überexpression des NOTCH-Zielgens HEY2 gezeigt werden. Die Deletionsanalyse des COUP-TFII Promotors lässt eine direkte Inhibition von COUP-TFII durch HEY2 vermuten. Die Überexpression von COUP-TFII führte zu einer starken Induktion der COUP-TFII mRNA- und Protein-Expression, jedoch weder in HEK 293T Zellen noch in Endothelzellen zu einer Änderung der HEY2 Promotoraktivität. Die Überexpression von FOXC1 und FOXC2 bewirkte eine Inhibition der HEY2 Promotoraktivität in HEK 293T Zellen. Die in der Arbeit gezeigte hohe Expression von FOXC1 in venösen Endothelzellen könnte somit in Kombination mit COUP-TFII für die komplette Repression der Aktivität des HEY2 Promotors in venösen Endothelzellen verantwortlich sein. Die durchgeführte Deletionsanalyse des HEY2 Promotors legt eine direkte Bindung von FOXC1 und FOXC2 an den HEY2 Promotor nahe. Die erzielten Ergebnisse dieser Arbeit sprechen im Kontext mit der Literatur für eine zelltypspezifische Regulierung/Aktivierung des NOTCH-Signalweges und lassen folgendes Modell zur Differenzierung des venösen oder arteriellen endothelialen Phänotyps vermuten: Die Determinierung des Phänotyps wird entschieden durch das Gleichgewicht der Expression der Interaktionspartner des NOTCH-Signalweges. Der VEGF Co-Rezeptor NRP1 und der VEGFR2 sind die entscheidenden Aktivatoren des NOTCH-Signalweges. Die Balance der Bindung des Repressors COUP-TFII an den NRP1 und VEGFR2 Promotor sowie des Aktivatorkomplexes NICD/RBP-JК an den NRP1 Promotor sind damit entscheidend für die Aktivität des NOTCH-Signalweges. NRP1 bindet VEGF und steigert gleichzeitig dessen Bindung an den VEGFR2. Dies führt zur Induktion von DLL4. Die Bindung von DLL4 an die NOTCH1/4 Rezeptoren führt zur Abspaltung der NOTCH intrazellulären Domäne (NICD) des Rezeptors. Die NICD wandert in den Zellkern und aktiviert dort zusammen im Komplex mit dem Transkriptionsfaktor RBP-JК die Gene HEY1, HEY2 und NRP1. Die Transkriptionsfaktoren HEY1 und HEY2 reprimieren über einen Feedback-Mechanismus direkt die Aktivität des COUP-TFII Promotors.